News
|
|
Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
After competing with 13 other semi-finalist start-ups at Harvard, Cloud was selected to travel and present in Chengdu, Sichuan Oct. 12-14 2018
Research Triangle Park, NC, October 4, 2018
Cloud Pharmaceuticals has been selected as a finalist in the U.S.-China Health Summit competition and was awarded travel and a presentation spot at the finals in Chengdu, Sichuan, China October 12-14, 2018.
As a key forum for promoting exchange in the health field, the Summit has been alternately hosted by U.S. and China, receiving continuous support from The National Health and Family Planning Commission of China and the U.S. Department of Health and Human Services.
Don Van Dyke, Cloud's Chief Operating Officer, made the winning presentation at Harvard University, School of Public Health, on September 8th. He said, "It was a great experience to be selected from a group of such fine early-stage companies. We appreciated the chance to show how Cloud's technology allows pharmaceutical companies to leap forward in the process of early design of novel therapies." The award sends Van Dyke to Chengdu to represent the company in the finals.
Since its inauguration in 2011 at Harvard University, the U.S.-China Health Summit (the Summit) has been dedicated to advancing global health by promoting exchange of knowledge, ideas and experiences among current and future health sector leaders from China, the U.S. and other countries. The annual Summit has been held alternately in the U.S. and China which gathers together hundreds of leaders from academia, governmental and non-governmental organizations as well as industry to discuss important challenges and opportunities in health sector reforms and development.
After competing with 13 other semi-finalist start-ups at Harvard, Cloud was selected to travel and present in Chengdu, Sichuan Oct. 12-14 2018
Research Triangle Park, NC, October 4, 2018
Cloud Pharmaceuticals has been selected as a finalist in the U.S.-China Health Summit competition and was awarded travel and a presentation spot at the finals in Chengdu, Sichuan, China October 12-14, 2018.
As a key forum for promoting exchange in the health field, the Summit has been alternately hosted by U.S. and China, receiving continuous support from The National Health and Family Planning Commission of China and the U.S. Department of Health and Human Services.
Don Van Dyke, Cloud's Chief Operating Officer, made the winning presentation at Harvard University, School of Public Health, on September 8th. He said, "It was a great experience to be selected from a group of such fine early-stage companies. We appreciated the chance to show how Cloud's technology allows pharmaceutical companies to leap forward in the process of early design of novel therapies." The award sends Van Dyke to Chengdu to represent the company in the finals.
Since its inauguration in 2011 at Harvard University, the U.S.-China Health Summit (the Summit) has been dedicated to advancing global health by promoting exchange of knowledge, ideas and experiences among current and future health sector leaders from China, the U.S. and other countries. The annual Summit has been held alternately in the U.S. and China which gathers together hundreds of leaders from academia, governmental and non-governmental organizations as well as industry to discuss important challenges and opportunities in health sector reforms and development.
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new therapies. Its proprietary Quantum Molecular Design process combines artificial intelligence (AI) and cloud computing to search virtual molecular space and applies along sophisticated molecular modeling to design novel drugs. The process enables faster drug development progress at lower cost and a higher success rate and better targeting of hard-to-drug indications. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications.
###